Growth and leadership Pace Life Sciences is expanding leadership with new President Andrew Fenny, signaling an upcoming phase of strategic growth and increased capacity for pharmaceutical and biotech clients across development stages.

Facility expansion Recent expansion of the Salem, New Hampshire site to establish a Center of Excellence for Aseptic Fill-Finish Processing presents opportunities to offer CMC development, regulatory support, and scale-up services to manufacturers seeking aseptic capabilities.

Strategic partnerships Collaborations such as the Cenevo digital lab transformation partnership indicate a propensity for integrated solutions; this opens openings to position end-to-end digitization, data management, and regulatory-compliance services.

Industry engagement Active participation in conferences and networking events, plus a focus on workforce development and cost-saving discussions, creates openings to propose training, compliance, and efficiency optimization programs for teams and partner sites.

Market positioning With a $250M–$500M revenue range and a broad CDMO service profile across CMC, CTM, and regulatory support, Pace is positioned to attract mid-to-large biopharma and gene therapy clients seeking reliable scale, quality, and fast program acceleration.